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Introduction 
Cidofovir was the first nucleotide analogue 
approved for clinical use. It reacts strongly against a 
variety of DNA viruses by competitively inhibiting 
DNA polymerase and blocking viral DNA synthesis 
and replication [1]. Although it was initially intended 
to treat cytomegalovirus (CMV) retinitis in patients 
with AIDS, recent findings suggest evidence that 
topical cidofovir is effective in treating a range of 
dermatologic conditions, including verruca vulgaris 
caused by human papilloma virus (HPV) infection. 
Since HIV infected individuals are at an increased risk 
for HPV infection, extensive research has examined 
the impact of cidofovir use in immunocompromised 
patients. An experimental study found that 1-3% 
topical cidofovir is effective in treating HPV lesions 
and molluscum contagiosum in adult patients with 
HIV/AIDS [2]. Case reports have also found topical 
cidofovir to effectively treat anogenital squamous 
cell carcinoma (SCC), bowenoid papulosis, 
condyloma acuminatum, Kaposi sarcoma, and HSV-II 
in adult patients with HIV/AIDS [3]. Cidofovir has 
experimentally been shown to be effective in 
treating genital condyloma acuminata in adult 
immunocompetent patients [4] and in a pediatric 
case [5]. 
Cidofovir has also been used in pediatric patients to 
cure verruca vulgaris recalcitrant to traditional 
treatment therapies. There have been several reports 
that topical 1-3% cidofovir cream applied once or 
twice daily is effective in treating verruca vulgaris 
with no systemic side effects and low rates of 
recurrence in immunocompetent children [6-8], as 
well as in immunocompromised children [9, 10]. 
These studies have used topical cidofovir to treat 
periungal, plantar, and anogenital verrucae as well as 
verrucous lesions on the hands and lips. It has been 
suggested that 1 to 3% concentration gives the best 
results on cutaneous lesions when applied twice 
daily. Topical cidofovir should be applied once daily, 
every other day, on delicate areas such as the lips, 
gums, and genitalia [2]. 
Topical cidofovir has been shown to be a relatively 
safe treatment, with the most common side effect 
being local irritation [8-9]. However, a single case of 
reversible nephrotoxicity related to topical cidofovir 
has been reported in a 28-year old 
immunosuppressed patient with chronic renal 
Abstract 
Cidofovir is an antiviral nucleotide analogue with 
relatively new treatment capacities for 
dermatological conditions, specifically verruca 
vulgaris caused by human papilloma virus infection. 
In a 10-year old boy with severe verruca vulgaris 
recalcitrant to multiple therapies, topical 1% 
cidofovir applied daily for eight weeks proved to be 
an effective treatment with no adverse side effects. 
This case report, in conjunction with multiple 
published reports, suggests that topical 1% cidofovir 
is a safe and effective treatment for viral warts in 
pediatric patients. 
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insufficiency. In this case, 4% cidofovir compounded 
in propylene glycol was applied on abraded skin [11]. 
Therefore, it is advised not to apply topical cidofovir 
to open wounds or in a concentration above 3%, 
especially in chronic renal disease patients. 
 
Case Synopsis 
A 10-year-old healthy boy, with no history of 
immunosuppression, presented to clinic with over 
50 verrucous papules distributed diffusely over the 
hands and face. The patient had periungual warts on 
nearly all fingers of both hands, multiple larger 
papules and plaques on the palmar surface, and a 
larger plaque at the base of his right dorsal thumb 
(Figure 1). On the face, he had two white filiform 
papules over the columella and one near the left 
lateral canthus (Figure 2). His mother reported that 
the warts first appeared three years prior on the 
hands and later spread to the face. Prior to  
 
Figure 1. Pre-treatment photo showing numerous verrucae on the dorsal hands and right palmar hand. 
 
Figure 2. Pre-treatment photo with several verruca over the 
columella of the nose and left lateral canthus. 
 
Figure 3. Post-treatment photo with resolution of verrucae over the right dorsal hand and right palmar hand. 
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presentation, the patient tried various topical 
formulations of salicylic acid (ranging from 17 to 
40%) without significant success. In clinic, he was first 
treated with intralesional Candida albicans antigen. 
The patient received two injections of 0.15ml 
Candida antigen each into two representative 
palmar lesions after the first visit. This was repeated 
over two more sessions, spaced three weeks apart, 
for a total of 0.9ml of intralesional Candida antigen. 
The patient was also started on oral cimetidine 
600mg twice daily, after the first visit. Four weeks 
after the third and final session of intralesional 
Candida injection, the patient still had no 
appreciable response and was prescribed 
compounded topical 1% cidofovir cream. A 1% 
formulation was chosen as it was the preferred 
compounded strength at the mail order Philadelphia 
Chemistry Rx Pharmacy; they were able to provide a 
15g tube for $225. No additional treatment 
modalities, such as topical salicylic acid were 
prescribed concurrently. Eight weeks after initiation 
of topical 1% cidofovir, applied once daily, with 
complete use of a single 15g tube of compounded  
medication, the patient returned for follow up and 
was noted to have near-complete resolution of all 
verrucae (Figures 3, 4). The patient had scattered 
hypopigmented macules at the site of resolved 
lesions on the dorsal hands but reported no systemic 
side effects and was overall very pleased with 
treatment. Six months after treatment there has 
been no report of recurrence. 
 
Case Discussion 
From a literature review performed of the available 
published reports in which topical cidofovir was 
used to treat warts, complete improvement was seen 
in 171 of 297 cases in immunocompetent patients 
and 44 of 59 cases in immunocompromised patients 
(Tables 1, 2). Similarly, partial improvement was 
seen in 89 of 297 cases in immunocompetent 
patients and 8 of 59 cases in immunocompromised 
patients (Tables 1, 2). 
As evidenced in this case, topical 1% cidofovir 
applied once daily for eight weeks proved to be an 
effective treatment of diffuse verrucae vulgaris in a 
child recalcitrant to multiple treatments including 
salicylic acid, oral cimetidine, and intralesional 
Candida antigen. This case adds to the growing body 
of evidence of the therapeutic efficacy of topical 
cidofovir for viral warts in both children and adults. 
As verruca vulgaris is particularly common in 
children and can prove difficult to treat, it is 
important to continue to investigate alternative 
treatment therapies. As the concentration and 
dosing schedule varies in published cases, clinical 
trials should be conducted to determine the ideal 
concentration of treatment and application  
Table 1. Non-Immunocompromised patients treated with topical cidofovir. 
 
 Complete improvement * Partial improvement** 
Aggregate Case reports [5, 27, 31, 32] 7/8  0/8 
Aggregate Retrospective studies [6-8, 12-15] 146/243 66/243 
Experimental studies  
 
Snoeck et al., 2001 [4] 9/19 7/19 
Coremans et al., 2003 [20] 
(37% of patients were immunocompromised) 9/27 16/27 
 
Figure 4. Post-treatment photo with resolution of verrucae over 
the face. 
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schedule. Consistent with our case, treatment should 
be stopped if there are no results after 10 -12 weeks, 
as improvement is usually seen within this amount of 
time [12]. 
 
Conclusion 
In the United States, topical cidofovir is not a 
routinely available medication and must be 
compounded prior to use, which leads to barriers in  
obtaining the medication for many patients. 
However, successful treatments outcomes, such as 
that seen in this patient, may help contribute to its 
establishment as a routinely available, safe, accepted 
treatment of verruca vulgaris. 
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